Radius Health Inc (NASDAQ: RDUS)

Radius Health, Inc., a biopharmaceutical company, focuses on developing therapeutics for patients with osteoporosis and other serious endocrine-mediated diseases in the United States. The company’s lead product comprises abaloparatide SC (BA058), a novel synthetic peptide analog of parathyroid hormone-related protein that is in Phase III clinical development for use in the reduction of fractures in postmenopausal osteoporosis; and Abaloparatide-TD, a line extension of abaloparatide-SC in the form of a transdermal patch that has completed Phase II clinical trial, which is used to increase bone mineral density.
Take a look at the 1-year chart of Radius (NASDAQ: RDUS) below with added notations:

RDUS embarked on an amazing rally in August of 2014, which took the stock all the way up to a high at $50 in February. From there, the stock hit $50 as resistance several more times forming a solid 52-week high resistance at $50 (green). Yesterday the stock broke through that level on strong volume, which should lead to higher prices overall.

The Tale of the Tape: RDUS broke its 52-week resistance at $50. The possible long position on the stock would be on a pullback down to that level with a stop placed under it. A break back below $50 could negate the forecast for a move higher.
Please share this article